Predict your next investment

GABA Therapeutics company logo
HEALTHCARE | Biotechnology
gabarx.com

See what CB Insights has to offer

Founded Year

2018

Stage

Unattributed | Alive

Total Raised

$21.5M

Last Raised

$21.5M | 2 yrs ago

About GABA Therapeutics

GABA Therapeutics is a biotech company focused on the treatment of mood disorders. GABA Therapeutics is developing GRX-917, an anxiety medication as effective as benzodiazepines like Xanax, but with minimal to no side effects. The drug's dual mechanism of action may also benefit a broad range of neuropsychiatric and neurological disorders.

GABA Therapeutics Headquarter Location

5000 Birch Street West Tower, Suite 3000

Newport Beach, California, 92660,

United States

855-875-4216

Latest GABA Therapeutics News

GABA Therapeutics and ATAI Life Sciences Partner to Develop a Novel GABA Modulator for the Treatment...

Sep 20, 2019

News provided by Share this article NEWPORT BEACH, Calif. and BERLIN, Sept. 20, 2019 /PRNewswire/ -- Today, GABA Therapeutics , a biotech company focused on the treatment of mood disorders, and ATAI Life Sciences , a global biotech company builder working on paradigm shifting interventions for unmet needs in the mental health space, announced a partnership to develop a novel compound that promises efficacy across a spectrum of mood disorders, particularly anxiety and depression. GABA Therapeutics' lead compound, GRX-917 , is a deuterated version of etifoxine, a safe and effective anxiolytic medication approved in approximately 40 countries with rapid onset and efficacy comparable to leading benzodiazepines like alprazolam (Xanax™) and lorazepam (Ativan™). In contrast to these and other benzodiazepines, however, more than 30 years of clinical experience with etifoxine suggest that GRX-917 is unlikely to produce serious side effects like sedation, amnesia, tolerance or physical dependence. "GABA's work with GRX-917 is critical for addressing the needs of millions of people living with treatment resistant mental illnesses," said Florian Brand, CEO & Co-Founder, ATAI Life Sciences. "By providing a safe way to meaningfully alleviate anxiety, not only will we improve peoples' quality of life, we'll also help them to better engage with their care providers." Notably, etifoxine is thought to achieve its anxiolytic activity by increasing central levels of neurosteroids, endogenous compounds (e.g. allopregnanolone) with potent antidepressant, neuroprotective, neurotrophic and anti-inflammatory properties, thereby affording GRX-917 the potential to treat a broad range of CNS diseases. With an improved pharmacokinetic profile that enables less frequent and lower dosing regimens, GRX-917 represents a leap forward for patients seeking to manage their anxiety acutely, safely and reliably. The Series A investment of up to $15.5 million will fund the program through a Phase 2a proof-of-concept study. "We are very pleased to partner with the team at ATAI," said Dr. Ian J. Massey , CEO, GABA. "They are building a world-class portfolio of mental health companies and GRX-917's potential to address the immense unmet medical need of unmanaged anxiety makes it a natural addition. We are grateful to have the funding and support of ATAI to drive forward this important program." "We are thrilled to partner with GABA and will fully support all efforts to bring GRX-917 to patients as quickly as possible," added Christian Angermayer, Founder, ATAI Life Sciences. About ATAI Life Sciences ATAI Life Sciences AG is a global biotech platform and company builder founded by Christian Angermayer. Based in Berlin, London and New York, its vision is to cure mental health disorders, enabling people to live healthier and happier lives. www.atai.life About GABA Therapeutics GABA Therapeutics is a California based biotechnology company focused on developing its lead compound GRX-917 for anxiety, depression and a broad range of neurological disorders. GRX-917 has the potential to become front-line therapy for anxiety and has composition-of-matter patent protection until 2036. Moreover, preclinical studies using etifoxine have demonstrated efficacy in a broad range of other neurological disorders, including pain, multiple sclerosis, epilepsy and Alzheimer's disease. For more detailed information on GABA Therapeutics, visit www.gabarx.com . About Anxiety Anxiety, which is frequently comorbid with depression, is the largest mental health issue in North America. It is estimated that one third of the North American adult population experiences anxiety issues, yet only one third of sufferers receive treatment, of whom only 10% experience any form of remission. This is largely due to limitations in current therapies. In 2018, there were approximately 140 million prescriptions of anxiety medications in the United States(2). (1)  anxietycentre.com Contact

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing GABA Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

GABA Therapeutics is included in 2 Expert Collections, including Biopharmaceuticals.

B

Biopharmaceuticals

13,989 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

GABA Therapeutics Patents

GABA Therapeutics has filed 2 patents.

The 3 most popular patent topics include:

  • Anxiolytics
  • Lactams
  • Prodrugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/21/2018

8/11/2020

Anxiolytics, Lactams, Prodrugs, Amines, Fluoroarenes

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

9/21/2018

00/00/0000

Grant Date

8/11/2020

00/00/0000

Title

Subscribe to see more

Related Topics

Anxiolytics, Lactams, Prodrugs, Amines, Fluoroarenes

Subscribe to see more

Status

Grant

Subscribe to see more

GABA Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

GABA Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.